Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06253806 · ClinicalTrials.gov registry record · Phase 2
Stellate Ganglion Block for COVID-induced Parosmia
A Phase 2 study of COVID-19-Induced Parosmia, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT06253806 is a Phase 2 study of COVID-19-Induced Parosmia that has completed, run by Washington University School of Medicine. The registered enrollment target is 48 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06253806, a Phase 2 study of COVID-19-Induced Parosmia, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
Chronic olfactory dysfunction, both hyposmia and parosmia, from the COVID-19 pandemic is a growing public health crisis with up to 1.2 million people in the United States affected. Olfactory dysfunction impacts one's quality of life significantly by decreasing the enjoyment of foods, creating environmental safety concerns, and affecting one's ability to perform certain jobs. Olfactory loss is also an independent predictor of anxiety, depression, and even mortality. Recent research by our group (unpublished data) and suggests that parosmias, moreso than hyposmias, can result in increased rates of anxiety, depression, and even suicidal ideation. While the pandemic has increased the interest by the scientific community in combating the burgeoning health crisis, few effective treatments currently exist for olfactory dysfunction. Persistent symptoms after an acute COVID-19 infection, or "Long COVID" symptoms, have been hypothesized to be a result of sympathetic positive feedback loops and dysautonomia. Stellate ganglion blocks have been proposed to treat this hyper-sympathetic activation by blocking the sympathetic neuronal firing and resetting the balance of the autonomic nervous system. Studies prior to the COVID-19 pandemic have supported a beneficial effect of stellate ganglion blocks on olfactory dysfunction, and recent news reports and a published case series have described a dramatic benefit in both olfactory function and other long COVID symptoms in patients receiving stellate ganglion blocks. A previous pilot study using stellate ganglion blocks of 20 participants with persistent COVID-19 olfactory dysfunction resulted modest improvements in subjective olfactory function, smell identification, and olfactory-specific quality-of-life, but it lacked a control group. Therefore, we propose a double-blinded, placebo-controlled randomized clinical trial assessing the efficacy of a stellate ganglion block versus saline injection in a total of up to 140 participants with
Conditions Studied
Interventions
- DRUG Stellate Ganglion Block
- DRUG Placebo Sham Injection
Study Locations (1)
Missouri
- Nyssa Fox Farrell - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2023-10-25 |
| Est. Completion | 2024-09-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06253806
The ClinicalTrials.gov registry entry for NCT06253806 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with COVID-19-Induced Parosmia appearing as the primary indexed condition, and to 2 interventions - of which Stellate Ganglion Block is the first listed.
NCT06253806 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT06253806 about?
NCT06253806 is a clinical study titled "Stellate Ganglion Block for COVID-induced Parosmia". Chronic olfactory dysfunction, both hyposmia and parosmia, from the COVID-19 pandemic is a growing public health crisis with up to 1.2 million people in the United States affected. Olfactory dysfunction impacts one's quality of life significantly by decreasing the enjoyment of foods, creating enviro...
What is the current status of trial NCT06253806?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2023-10-25. Estimated completion is 2024-09-16.
What conditions does trial NCT06253806 study?
This clinical trial studies the following conditions: COVID-19-Induced Parosmia.
What interventions are being tested in trial NCT06253806?
The interventions under investigation include: Stellate Ganglion Block (DRUG), Placebo Sham Injection (DRUG).
Who is sponsoring clinical trial NCT06253806?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06253806 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.